课题基金 / 基金详情

Serotonin modulated mitochondrial dysfunction in Depression Diabetes and Dementia (3Ds)

Serotonin modulated mitochondrial dysfunction in Depression Diabetes and Dementia (3Ds)
抑郁症、糖尿病和痴呆症 (3D) 中血清素调节线粒体功能障碍
批准号:
10561624
负责人:
Arubala Parlapalle Reddy
金额:
$51.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-02-15 至 2027-01-31

项目摘要

项目成果

Arubala Parlapalle Reddy的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Our research aims to understand the role of serotonin modulated mitochondrial biogenesis in diabetes, depression, and dementia (Alzheimer's disease, AD). Diabetes and depression are independent risk factors for dementia and worsen the dementia pathology and therapeutic response. Depression comorbidity impaired metabolic function such as hyperglycemia, insulin resistance, inflammation, and oxidative stress results in physical depression and cognitive impairment. Serotonin is an essential neurotransmitter that performs synaptic transmission, plasticity, energy homeostasis in aging and dementia. For a long time, it is known that the brainstem harbors unique neurons to synthesize and project serotonin to the entire central nervous system. However, molecular links between serotonin levels and mitochondrial biogenesis, mitochondrial dynamics, mitophagy/autophagy in dementia, diabetes, and depression are not entirely understood. It is established that serotonin synthesis in dorsal raphe is protective and essential for cell homeostasis and energy metabolism. It has been hypothesized that low serotonin levels induce defective mitochondrial biogenesis, impaired mitochondrial dynamics, mitochondrial dysfunction and defective mitophagy/autophagy in depression, diabetes, and dementia, and selective serotonin reuptake inhibitors, such as citalopram treatment reverses defective mitochondrial biogenesis and all mitochondrial defective aspects. We have conceptualized the study in rodents focusing on the transgenic models of 3Ds focusing hippocampus (APP, Tau, HT22 cells), hypothalamus (DbDb, mHypo cells), and raphe (TPH2/ko, RN46A-B14 cells). Therefore, the current study proposes to understand the pathologies and the protective effects of citalopram (SSRI) against defective mitochondrial biogenesis, impaired mitochondrial dynamics, and defective mitophagy/autophagy. The outcome of our proposed experiments will provide new insights into the role of serotonin in depression, diabetes, and dementia concerning mitochondrial biogenesis, mitochondrial dynamics, mitochondrial function, and mitophagy/autophagy. The outcome will also provide beneficial effects of citalopram against common serotonin-induced defects of mitochondrial dynamics, mitochondrial function, and mitophagy/autophagy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Serotonin modulated mitochondrial dysfunction in Depression Diabetes and Dementia (3Ds)
  • 批准号:
    10367711
  • 项目类别:
  • 资助金额:
    $51.08万
  • 财政年份:
    2022
  • 负责人:
    Arubala Parlapalle Reddy
  • 依托单位:
Differential Expression of Brainstem Neurotransmitters in Alzheimer's Disease and Alzheimer's Dementia Related Diseases
  • 批准号:
    10017149
  • 项目类别:
  • 资助金额:
    $15.08万
  • 财政年份:
    2019
  • 负责人:
    Arubala Parlapalle Reddy
  • 依托单位:
Differential Expression of Brainstem Neurotransmitters in Alzheimer's Disease and Alzheimer's Dementia Related Diseases
  • 批准号:
    10051004
  • 项目类别:
  • 资助金额:
    $15.0万
  • 财政年份:
    2019
  • 负责人:
    Arubala Parlapalle Reddy
  • 依托单位:
Differential Expression of Brainstem Neurotransmitters in Alzheimer's Disease and Alzheimer's Dementia Related Diseases
  • 批准号:
    10286284
  • 项目类别:
  • 资助金额:
    $15.3万
  • 财政年份:
    2019
  • 负责人:
    Arubala Parlapalle Reddy
  • 依托单位:
海外基金